Drug: Venetoclax (Venclexta, AbbVie/Genentech)
Status: Granted breakthrough designation for use in combination with low-dose cytarabine (LDAC) for older patients with acute myeloid leukemia who are ineligible for intensive chemotherapy
Significant Information:
- Venetoclax is a small molecule developed to selectively bind and inhibit the BCL-2 protein, which is important in apoptosis (programmed cell death)
- BCL-2 is believed to restore the signaling system in charge that tells cells to